NEO

+ Watchlist + Portfolio

NeoGenomics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $16.66
52-Week Range: $5.94 – $16.92
Market Cap: $2.12B
P/E (TTM): —
EPS (TTM): -0.39
Dividend Yield: —

Advanced Metrics

Price/Book: 2.69
PEG Ratio: 2.09
Return on Equity: -6.33%
Return on Assets: -1.89%
Gross Margin: 43.92%
Operating Margin: -4.84%
Profit Margin: -6.77%
Current Ratio: 3.60
Debt/Equity: 0.57
Total Debt: $448.37M
Free Cash Flow: $43.90M
Revenue Growth: 11.20%
Earnings Growth: —
Enterprise Value: $2.43B

NEO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$509.73M	$591.64M	$660.57M	$727.33M
Cost of Revenue	$321.83M	$347.04M	$370.47M	$413.04M
Gross Profit	$187.90M	$244.60M	$290.10M	$314.29M
Research & Development	$30.33M	$27.31M	$31.16M	$37.08M
Selling, General & Admin	$277.91M	$279.96M	$310.49M	$331.65M
Operating Expenses	$341.00M	$341.25M	$375.55M	$402.42M
Operating Income	-$153.11M	-$96.65M	-$85.45M	-$88.13M
EBITDA	-$82.33M	-$17.61M	-$1.51M	-$38.69M
Pretax Income	-$159.34M	-$97.10M	-$80.67M	-$110.27M
Income Tax	-$15.09M	-$9.13M	-$1.95M	-$2.24M
Net Income	-$144.25M	-$87.97M	-$78.73M	-$108.03M
Diluted EPS	-1.16	-0.70	-0.62	-0.84
Diluted Shares	124.22M	125.50M	126.66M	128.10M

NEO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$263.18M	$342.49M	$367.01M	$159.62M
Receivables	$119.71M	$131.23M	$150.54M	$159.24M
Inventory	$24.28M	$24.16M	$26.75M	$28.57M
Current Assets	$605.29M	$596.81M	$596.02M	$376.29M
Total Assets	$1.74B	$1.68B	$1.64B	$1.36B
Current Liabilities	$89.93M	$96.30M	$301.24M	$88.30M
Long-Term Debt	$535.32M	$538.20M	$340.33M	$341.86M
Total Debt	$610.93M	$611.68M	$605.33M	$409.46M
Total Liabilities	$742.01M	$739.69M	$735.70M	$523.27M
Retained Earnings	-$159.09M	-$247.06M	-$325.78M	-$433.81M
Shareholders' Equity	$998.02M	$941.54M	$902.34M	$836.56M
Working Capital	$515.36M	$500.51M	$294.78M	$287.99M
Net Debt	$272.14M	$195.71M	$174.10M	$182.24M

NEO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$65.99M	-$1.95M	$7.02M	$5.23M
Capital Expenditure	-$30.89M	-$28.75M	-$41.06M	-$27.01M
Free Cash Flow	-$96.88M	-$30.70M	-$34.04M	-$21.78M
Depreciation & Amortisation	$69.43M	$72.58M	$72.55M	$67.82M
Stock-Based Compensation	$24.67M	$24.63M	$33.41M	$41.32M
Investing Cash Flow	$517.00K	$76.71M	$12.86M	-$12.34M
Financing Cash Flow	$11.83M	$4.55M	$4.65M	-$200.29M
Net Change in Cash	-$53.65M	$79.31M	$24.52M	-$207.39M

NEO Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$181.33M	$187.80M	$190.17M	$186.67M	$201.66M
Cost of Revenue	$104.07M	$107.35M	$106.83M	$105.81M	$109.78M
Gross Profit	$77.26M	$80.45M	$83.34M	$80.86M	$91.88M
Research & Development	$9.02M	$8.69M	$9.18M	$9.53M	$10.76M
Selling, General & Admin	$95.82M	$91.68M	$53.26M	$89.57M	$90.89M
Operating Expenses	$104.84M	$100.37M	$96.13M	$99.11M	$101.65M
Operating Income	-$27.59M	-$19.93M	-$12.79M	-$18.24M	-$9.77M
EBITDA	-$27.62M	-$9.35M	$4.59M	-$567.00K	$18.82M
Pretax Income	-$45.82M	-$26.39M	-$12.41M	-$17.58M	$1.83M
Income Tax	-$724.00K	$740.00K	-$2.52M	-$472.00K	-$412.00K
Net Income	-$45.09M	-$27.13M	-$9.88M	-$17.11M	$2.24M
Diluted EPS	-0.35	-0.21	-0.08	-0.13	0.02
Diluted Shares	127.95M	128.41M	128.65M	129.17M	130.83M

NEO Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$154.72M	$164.12M	$159.62M	$146.14M	$145.54M
Receivables	$153.13M	$155.30M	$159.24M	$167.42M	$175.41M
Inventory	$34.17M	$28.46M	$28.57M	$29.84M	$27.14M
Current Assets	$392.55M	$382.46M	$376.29M	$373.68M	$381.48M
Total Assets	$1.39B	$1.37B	$1.36B	$1.35B	$1.35B
Current Liabilities	$100.12M	$97.87M	$88.30M	$84.59M	$105.88M
Long-Term Debt	$341.10M	$341.48M	$341.86M	$342.24M	$374.24M
Total Debt	$411.76M	$410.31M	$409.46M	$408.53M	$448.37M
Total Liabilities	$539.91M	$536.49M	$523.27M	$517.77M	$566.51M
Retained Earnings	-$396.80M	-$423.93M	-$433.81M	-$450.91M	-$448.67M
Shareholders' Equity	$854.04M	$838.29M	$836.56M	$828.76M	$785.73M
Working Capital	$292.43M	$284.60M	$287.99M	$289.09M	$275.60M
Net Debt	$186.37M	$177.36M	$182.24M	$196.10M	$228.70M

NEO Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$20.33M	$8.88M	$1.34M	-$8.14M	$19.96M
Capital Expenditure	-$6.32M	-$8.31M	-$7.87M	-$5.00M	-$8.22M
Free Cash Flow	$14.01M	$570.00K	-$6.53M	-$13.14M	$11.74M
Depreciation & Amortisation	$17.26M	$16.44M	$16.39M	$16.41M	$16.21M
Stock-Based Compensation	$12.21M	$10.31M	$8.04M	$9.64M	$8.22M
Investing Cash Flow	-$9.31M	-$277.00K	-$6.30M	-$5.00M	-$8.32M
Financing Cash Flow	-$202.43M	$765.00K	$431.00K	-$338.00K	-$12.24M
Share Repurchases	—	—	—	-$338.00K	-$24.66M
Net Change in Cash	-$191.42M	$9.37M	-$4.53M	-$13.47M	-$604.00K

Market Snapshot

About

NeoGenomics, Inc. provides cancer-focused genetic testing and diagnostics services. The company offers molecular and cytogenetic testing, pathology services, and clinical trials support to oncologists, hospitals, and pharmaceutical clients.